Christopher Primiano
General Counsel
Karyopharm Therapeutics Inc. (KPTI)Equibles does not estimate personal net worth.
Get an email with a short summary when Karyopharm Therapeutics Inc. publishes a filing, an earnings call transcript or a press release.
Get KPTI alertsAbout Christopher Primiano
Christopher Primiano is recorded as General Counsel at Karyopharm Therapeutics Inc. (KPTI). The proxy statement of Karyopharm Therapeutics Inc. reports total compensation of $1,623,347 for Christopher Primiano in fiscal 2019, including a base salary of $418,200. Disclosed compensation is on record for 2 fiscal years. Karyopharm Therapeutics Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Karyopharm Therapeutics Inc. includes Richard Paulson (CEO and Board Member), Senior Clinical (CEO), Michael Mano (General Counsel) and 7 others.
Affiliation history
-
Current
-
Aura Biosciences, Inc. (AURA)
Proxy statement
Start not stated–2022-04-28
Last confirmed by a filing; no departure on record
Company network
Leadership on record at Karyopharm Therapeutics Inc.
- Richard Paulson CEO, Board Member
- Senior Clinical CEO
- Michael Mano General Counsel
- Kristin Abate Chief Accounting Officer
- Barry E. Greene Board Member
- Chen Schor Board Member
- Christy J Oliger Board Member
- Christy J. Oliger Board Member
- Deepika R. Pakianathan Board Member
- Garen G. Bohlin Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2019 | Karyopharm Therapeutics Inc. (KPTI) | J.D., M.B.A. Executive Vice President, Chief Business Officer, General Counsel and Secretary | $418,200 | $1,623,347 |
| 2018 | Karyopharm Therapeutics Inc. (KPTI) | J.D., M.B.A. Executive Vice President, Chief Business Officer, General Counsel and Secretary | $404,000 | $1,522,593 |
Recent activity
No call appearances or filed executive changes recorded yet.